{"title":"<i>Antheraea proylei</i> J. Sericin Induces Apoptosis in a Caspase-dependent Manner in A549 and HeLa Cells.","authors":"Potsangbam Jolly Devi, Asem Robinson Singh, Naorem Tarundas Singh, Laishram Rupachandra Singh, Sanjenbam Kunjeshwori Devi, Lisam Shanjukumar Singh","doi":"10.2174/1871520623666230329123437","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In spite of much progress in cancer, the global cancer burden is still significant and increasing. Sericin, an adhesive protein of silk cocoons, has been shown to be a potential protein in various biomedical applications, including cancer therapeutics. The present study evaluates the anticancer property of sericin from cocoons of <i>Antheraea proylei</i> J (SAP) against human lung cancer (A549) and cervical cancer (HeLa) cell lines. This is the first report of anti-cancer activity of the non-mulberry silkworm <i>A. proylei</i> J.</p><p><strong>Objective: </strong>Establish the antiproliferative potential of SAP. 2. Identify the molecular mechanism of cell death induced by SAP on two different cell lines.</p><p><strong>Aims: </strong>To investigate the anticancer activity of sericin preparation from cocoons of <i>A. proylei</i>.</p><p><strong>Methods: </strong>SAP was prepared from cocoons of <i>A. proylei</i> J. by the process of the degumming method. Cytotoxic activity was assessed by MTT assay, and genotoxicity was assessed by comet assay. Cleavage of caspase and PARP proteins and phosphorylation of MAPK pathway members were analysed by Western blotting. Cell cycle analysis was done by flow cytometer.</p><p><strong>Results: </strong>SAP causes cytotoxicity to A549 and HeLa cell lines with the IC<sub>50</sub> values 3.8 and 3.9 μg/μl respectively. SAP induces apoptosis in a dose-dependent manner through caspase-3 and p38, MAPK pathways in A549 and HeLa cells. Moreover, in A549 and HeLa cells, SAP induces cell cycle arrest at the S phase in a dose-dependent manner.</p><p><strong>Conclusion: </strong>The difference in the molecular mechanisms of apoptosis induced by SAP in A549 and HeLa cell lines may be due to the difference in the genotypes of the cancer cell lines. However, further investigation is warranted. The overall results of the present study envisage the possibility of using SAP as an anti-tumorigenic agent.</p>","PeriodicalId":7934,"journal":{"name":"Anti-cancer agents in medicinal chemistry","volume":" ","pages":"709-717"},"PeriodicalIF":2.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer agents in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871520623666230329123437","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In spite of much progress in cancer, the global cancer burden is still significant and increasing. Sericin, an adhesive protein of silk cocoons, has been shown to be a potential protein in various biomedical applications, including cancer therapeutics. The present study evaluates the anticancer property of sericin from cocoons of Antheraea proylei J (SAP) against human lung cancer (A549) and cervical cancer (HeLa) cell lines. This is the first report of anti-cancer activity of the non-mulberry silkworm A. proylei J.
Objective: Establish the antiproliferative potential of SAP. 2. Identify the molecular mechanism of cell death induced by SAP on two different cell lines.
Aims: To investigate the anticancer activity of sericin preparation from cocoons of A. proylei.
Methods: SAP was prepared from cocoons of A. proylei J. by the process of the degumming method. Cytotoxic activity was assessed by MTT assay, and genotoxicity was assessed by comet assay. Cleavage of caspase and PARP proteins and phosphorylation of MAPK pathway members were analysed by Western blotting. Cell cycle analysis was done by flow cytometer.
Results: SAP causes cytotoxicity to A549 and HeLa cell lines with the IC50 values 3.8 and 3.9 μg/μl respectively. SAP induces apoptosis in a dose-dependent manner through caspase-3 and p38, MAPK pathways in A549 and HeLa cells. Moreover, in A549 and HeLa cells, SAP induces cell cycle arrest at the S phase in a dose-dependent manner.
Conclusion: The difference in the molecular mechanisms of apoptosis induced by SAP in A549 and HeLa cell lines may be due to the difference in the genotypes of the cancer cell lines. However, further investigation is warranted. The overall results of the present study envisage the possibility of using SAP as an anti-tumorigenic agent.
Antheraea proylei J. Sericin 在 A549 和 HeLa 细胞中以 Caspase 依赖性方式诱导细胞凋亡。
背景:尽管癌症研究取得了很大进展,但全球癌症负担仍然很重,而且还在不断增加。丝胶是蚕茧的一种粘合蛋白,已被证明是一种可用于各种生物医学应用(包括癌症治疗)的潜在蛋白。本研究评估了 Antheraea proylei J(SAP)蚕茧中的丝胶蛋白对人类肺癌(A549)和宫颈癌(HeLa)细胞系的抗癌特性。这是首次报道非桑蚕 A. proylei J 的抗癌活性:确定 SAP 的抗增殖潜力。2.2. 确定 SAP 在两种不同细胞系上诱导细胞死亡的分子机制。目的:研究从 A. proylei 茧中提取的丝胶制剂的抗癌活性:用脱胶法从 A. proylei J. 的茧中制备 SAP。细胞毒活性用 MTT 法评估,遗传毒性用彗星试验评估。通过 Western 印迹分析了 Caspase 和 PARP 蛋白的裂解情况以及 MAPK 通路成员的磷酸化情况。细胞周期分析由流式细胞仪完成:SAP对A549和HeLa细胞株具有细胞毒性,IC50值分别为3.8和3.9 μg/μl。在 A549 和 HeLa 细胞中,SAP 通过 caspase-3 和 p38、MAPK 通路以剂量依赖性方式诱导细胞凋亡。此外,在 A549 和 HeLa 细胞中,SAP 以剂量依赖性方式诱导细胞周期停滞在 S 期:结论:SAP在A549和HeLa细胞系中诱导细胞凋亡的分子机制不同,可能是由于癌细胞系的基因型不同。不过,还需要进一步研究。本研究的总体结果为将 SAP 用作抗肿瘤药物提供了可能性。
期刊介绍:
Formerly: Current Medicinal Chemistry - Anti-Cancer Agents.
Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents.
Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication.
Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.